Format

Send to

Choose Destination
Xenotransplantation. 2019 Jul 25:e12544. doi: 10.1111/xen.12544. [Epub ahead of print]

Regenerative cell therapy for the treatment of hyperbilirubinemic Gunn rats with fresh and frozen human induced pluripotent stem cells-derived hepatic stem cells.

Author information

1
INSERM, UMRS 1064-Center for Research in Transplantation and Immunology, Nantes, France.
2
CHU Hôtel Dieu, Institut de Transplantation Urologie Néphrologie, Nantes, France.
3
Université de Nantes, Faculté de Médecine, Nantes, France.
4
GoLiver Therapeutics, Institut de Recherche en Santé de l'Université de Nantes, Nantes, France.
5
Transgenesis Rat ImmunoPhenomic platform, INSERM 1064, SFR Francois Bonamy, CNRS UMS3556, Nantes, France.
6
Service de Biologie, Groupe Hospitalier Saint Joseph, Paris, France.
7
Laboratoire de génétique moléculaire, Hôpital Antoine Béclère, Clamart, France.
8
Unidad de Hepatología Experimental, Instituto de Investigación Sanitaria La Fe, Valencia, Spain.
9
APHP, CRMR Maladies Héréditaires du Métabolisme Hépatique, Hôpital Antoine Béclère, Clamart, France.
10
UFR Kremlin Bicêtre, Université paris Sud Paris Saclay, Le Kremlin-Bicêtre, France.
11
INSERM U1169, Le Kremlin-Bicêtre, France.
12
Department of Surgery, Anne McLaren Laboratory for Regenerative Medicine, Wellcome-Medical Research Council Cambridge Stem Cell Institute, University of Cambridge, Cambridge, UK.
13
CRCINA INSERM U1232, Institut de Recherche en Santé de l'Université de Nantes, Nantes, France.

Abstract

Pluripotent stem cells have been investigated as a renewable source of therapeutic hepatic cells, in order to overcome the lack of transplantable donor hepatocytes. Whereas different studies were able to correct hepatic defects in animal models, they focused on the most mature phenotype of hepatocyte-like cells (HLCs) derived from pluripotent stem cells and needed freshly prepared cells, which limits clinical applications of HLCs. Here, we report the production of hepatic stem cells (pHSCs) from human-induced pluripotent stem cells (hiPSCs) in xeno-free, feeder-free, and chemically defined conditions using as extracellular matrix a recombinant laminin instead of Matrigel, an undefined animal-derived matrix. Freshly prepared and frozen pHSCs were transplanted via splenic injection in Gunn rats, the animal model for Crigler-Najjar syndrome. Following cell transplantation and daily immunosuppression treatment, bilirubinemia was significantly decreased (around 30% decrease, P < .05) and remained stable throughout the 6-month study. The transplanted pHSCs underwent maturation in vivo to restore the deficient metabolic hepatic function (bilirubin glucuronidation by UGT1A1). In conclusion, we demonstrate for the first time the differentiation of hiPSCs into pHSCs that (a) are produced using a differentiation protocol compatible with Good Manufacturing Practices, (b) can be frozen, and (c) are sufficient to demonstrate in vivo therapeutic efficacy to significantly lower hyperbilirubinemia in a model of inherited liver disease, despite their immature phenotype. Thus, our approach provides major advances toward future clinical applications and would facilitate cell therapy manufacturing from human pluripotent stem cells.

KEYWORDS:

Crigler-Najjar syndrome; Gunn rats; hepatocyte-like cells; induced pluripotent stem cells; regenerative medicine

PMID:
31342573
DOI:
10.1111/xen.12544

Supplemental Content

Full text links

Icon for Wiley
Loading ...
Support Center